Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex
暂无分享,去创建一个
E. Crawford | H. Scher | P. Nieh | W. Kelly | E. David Crawford | Peter T. Nieh | Howard I. Scher | William K. Kelly
[1] P. Carroll,et al. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. , 1994, Urology.
[2] M. Koutsilieris,et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.
[3] H. Scher,et al. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Scher,et al. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.
[5] J. Veldscholte,et al. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. , 1992, Biochemistry.
[6] G. Kennealey,et al. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. , 1991, The Urologic clinics of North America.
[7] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[8] J. Aisner,et al. Tamoxifen withdrawal response. Report of a case. , 1989, Archives of internal medicine.
[9] M. Chen,et al. Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens , 1989, The Prostate.
[10] F. Labrie,et al. Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. , 1988, Journal of the National Cancer Institute.
[11] P. Band,et al. Tamoxifen-induced tumor stimulation and withdrawal response. , 1979, Cancer treatment reports.